Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach

Contributed by: Business Wire

Logo

Tags

Research

Other Health

General Health

Oncology

Consumer

Technology

Artificial Intelligence

Health Technology

Clinical Trials

Science

Biotechnology

Women

Health

Agendia, Inc.

More Like This

Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 2026

Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress

Personalized biology-based insights (Graphic: Business Wire)

Agendia, Inc. Provides Review of Successful 2024

Agendia Achieves CE-IVDR Certification for its MammaPrint® and BluePrint® Breast Cancer Assays

(Graphic: Business Wire)

MammaPrint® Reimbursement Indication Extended in Belgium

Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study

(Graphic: Business Wire)

Agendia Announces Publication Validating MammaPrint® Utility in Prediction of Extended Endocrine Therapy Benefit